Sign Out
Each Monitored Release Tablet contains: Trimetazidine (as dihydrochloride) 35 mg.
Trimetazidine is a cardiovascular drug that acts as an effective anti-anginal agent by modulating cardiac energy metabolism. It is an anti-ischaemic metabolic agent that improves myocardial glucose utilization through inhibition of fatty acid metabolism. By preserving the energy metabolism in cells exposed to hypoxia or ischaemia. Trimetazidine prevents a decrease in intracellular adenosine triphosphate levels, thereby ensuring the proper functioning of ionic pumps and transmembranous sodium-potassium flow while maintaining cellular homeostasis. Trimetazidine also inhibits the oxidation of fatty acid in blood vessels.
